About FDALive
At FDALive, we are always interested in hearing from our customers.
FDALive Mailing Address:
11800 Nebel Street
Rockville, Maryland 20852-2508
Get Directions On Google Maps
View Larger Map
Telephone
301.984.0001
Fax
301.984.8954
E-mail:
FDALive General Information - info@fdalive.com
FDALive Sales - sales@fdalive.com
FDALive Technical Support - support@fdalive.com
Upcoming Meetings
Joint Gastrointestinal & DSRM AdComm - Sponsor: Sloan Pharma
Meeting Date: 10/17/18-10/17/18
Meeting Details:
The committees will discuss supplemental new drug application (sNDA) 021200, supplement 015, for ZELNORM (tegaserod maleate) tablets for oral administration, submitted by Sloan Pharma S.[agrave].r.l, Bertrange, Cham Branch, proposed for the treatment of women with irritable bowel syndrome with constipation who do not have a history of cardiovascular ischemic disease, such as myocardial infarction, stroke, transient ischemic attack, or angina, and who do not have more than one risk factor for cardiovascular disease.
| Location: | Pooks Hill | Related News Links: | Not Available |
| Time: | 8:00AM-5:00PM | ||
| Materials: | |||
- Gastrointestinal Drugs AdComm - Sponsor: Shire
Meeting Date: 10/18/18-10/18/18
Meeting Details:
The committee will discuss new drug application (NDA) 210166 for prucalopride tablets for oral administration, submitted by Shire Development, LLC, proposed for the treatment of chronic idiopathic constipation in adults.
| Location: | Pooks Hill | Related News Links: | Not Available |
| Time: | 8:00AM-5:00PM | ||
| Materials: | |||
- Endocrinologic and Metabolic Drugs AdComm
Meeting Date: 10/24/18-10/25/18
Meeting Details:
Agenda: On both days, the committee will discuss the ``Guidance for Industry: Diabetes Mellitus--Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes' (https://www.fda.gov/downloads/Drugs/Guidances/ucm071627.pdf), and the cardiovascular risk assessment of drugs and biologics for the treatment of type 2 diabetes mellitus.
| Location: | FDA Meeting Room | Related News Links: | Not Available |
| Time: | 8:00AM-5:00PM | ||
| Materials: | |||
- Joint Psychopharmacologic & DSRM AdComm - Sponsor: Alkermes Inc.
Meeting Date: 11/1/18-11/1/18
Meeting Details:
The committees will discuss efficacy, safety and risk-benefit profile of new drug application (NDA) 210417 for buprenorphine and samidorphan sublingual tablets, submitted by Alkermes, Inc., for adjunctive treatment of major depressive disorder.
| Location: | FDA Meeting Room | Related News Links: | Not Available |
| Time: | 8:00AM-5:00PM | ||
| Materials: | |||
- Patient Engagement AdComm
Meeting Date: 11/15/18-11/15/18
Meeting Details:
On November 15, 2018, the Committee will discuss and make recommendations on the topic “Connected and Empowered Patients: e-Platforms Potentially Expanding the Definition of Scientific Evidence.” The recommendations will address how FDA can leverage patient-driven platforms, such as social media and registries, to better engage patients and consumers as empowered partners in the work of protecting public health and promoting responsible innovation. Social media and other web platform enablers are facilitating the growth of virtual patient communities. Increasingly, patients and health care consumers are using these platforms to share their health experiences and seek information from other patients and consumers, rather than their health care providers alone. Novel approaches and methodologies are being used to tap into some of these platforms as potentially rich sources of patient-generated health data, which could be used as relevant and reliable real-world evidence. This meeting will help advance FDA’s objective to assure the needs, experiences, and perspectives of patients are included as part of FDA’s deliberations involving the regulation of medical devices and their use by patients. For this meeting, FDA is seeking input from the Committee and the public on whether and how FDA can harness the emerging potential of these patient platforms to better engage patients and consumers as empowered partners in the work of protecting public health and promoting responsible innovation. In addition, FDA is seeking recommendations from the Committee on ways to leverage these platforms to disseminate as well as potentially collect and evaluate health information to and from patients and consumers.
| Location: | Hilton Washington DC North/Gaithersburg | Related News Links: | Not Available |
| Time: | 8:00AM-5:00PM | ||
| Materials: | |||
Recent Meetings
Anesthetic & Analgesic Drug Products AdComm - Sponsor: AcelRX
Meeting Date: 10/12/18-10/12/18
Meeting Details:
The committee will be asked to discuss new drug application (NDA) 209128, sufentanil sublingual tablets, submitted by AcelRx Pharmaceuticals, Inc., for the management of moderate-to-severe acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate, in adult patients in a medically supervised setting. The committee will also be asked to discuss risk- benefit considerations and whether this product should be approved.
| Location: | FDA Meeting Room | Related News Links: | Not Available |
| Time: | 8:00AM-5:00PM | ||
| Materials: | |||
- Anesthetic & Analgesic Drug Products AdComm - Sponsor: Trevena Inc.
Meeting Date: 10/11/18-10/11/18
Meeting Details:
The committee will be asked to discuss new drug application (NDA) 210730, for oliceridine 1 milligram/milliliter injection, submitted by Trevena, Inc., for the management of moderate-to-severe acute pain in adult patients for whom an intravenous opioid is warranted. The committee will also be asked to discuss the efficacy and safety data and benefit-risk considerations.
| Location: | FDA Meeting Room | Related News Links: | Not Available |
| Time: | 8:00AM-5:00PM | ||
| Materials: | |||
- Oncologic Drugs AdComm - Sponsor: Genentech & Celltrion
Meeting Date: 10/10/18-10/10/18
Meeting Details:
The committee will discuss biologics license application 761088 for CT-P10, a proposed biosimilar to Genentech, Inc.'s RITUXAN (rituximab), submitted by Celltrion, Inc. The proposed indications (uses) for this product are for the treatment of adult patients with (1) relapsed or refractory, low-grade or follicular, CD20-positive, B- cell Non-Hodgkin's Lymphoma (NHL) as a single agent; (2) previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to CT-P10 in combination with chemotherapy, as single- agent maintenance therapy; and (3) non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone.
| Location: | FDA Meeting Room | Related News Links: | Not Available |
| Time: | 8:00AM-1:00PM | ||
| Materials: | |||
- Neurological Devices Panel - Sponsor: Sequent Medical, Inc.
Meeting Date: 9/27/18-9/27/18
Meeting Details:
On September 27, 2018, the Committee will discuss, make recommendations, and vote on the premarket approval application sponsored by Sequent Medical, Inc. for the Woven Endobridge (WEB) Aneurysm Embolization System, which is intended to treat wide-neck intracranial aneurysms arising or located at a vessel bifurcation. The WEB device is being evaluated in the WEB Intrasaccular Therapy Study (WEB-IT): a multicenter, prospective, non-randomized investigation. The Committee will be asked to review the clinical data from the WEB-IT study to help the Agency assess the safety and effectiveness of the device for the proposed indications for use.
| Location: | Hilton GB | Related News Links: | Not Available |
| Time: | 8:00AM-5:00PM | ||
| Materials: | |||
- Pharmaceutical Science and Clinical Pharmacology AdComm
Meeting Date: 9/20/18-9/20/18
Meeting Details:
The meeting will focus on two topics related to the Office of Pharmaceutical Quality’s priority of promoting the availability of better medicine. During the morning session, the committee will discuss the modernization of assessing drug applications through a Knowledge-Aided Assessment and Structured Application (KASA) initiative. FDA will seek input on the potential enhancement of a submission format consistent with KASA to improve the efficiency and consistency of regulatory quality assessment. During the afternoon session, the committee will discuss in-vitro/in-vivo relationship standards, and will seek input on establishing patient-focused dissolution standards for oral solid modified-release dosage forms.
| Location: | FDA Meeting Room | Related News Links: | Not Available |
| Time: | 8:00AM-5:00PM | ||
| Materials: | |||
- Pediatric AdComm
Meeting Date: 9/20/18-9/20/18
Meeting Details:
On Thursday, September 20, 2018, the PAC will meet to discuss pediatric-focused safety reviews, as mandated by the Best Pharmaceuticals for Children Act (Pub. L. 107-109) and the Pediatric Research Equity Act of 2003 (Pub. L. 108-155). The PAC will meet to discuss the following Center for Drug Evaluation and Research products: INTUNIV LEXAPRO The FDA will provide general safety updates including updates on the following topics without vote by the committee: Overview of FAERS and lack of efficacy; Generic drug approval process; and discussion on trade versus generic drugs; exceptions; Summary of FDA completed review of pediatric safety issues and updated labeling changes for Exjade (deferasirox); Update labeling change for inhaled corticosteroid long-acting ß-2 agonists (ICS/LABAs); Safety labeling for gadolinium.
| Location: | FDA Meeting Room | Related News Links: | Not Available |
| Time: | 8:30AM-4:00PM | ||
| Materials: | |||
Past Meetings
Below is a listing of all committees. Select a committee to display all meetings available for that committee.
Live Meetings
There are no Live Broadcasts available at this time.
Sign in to FDALive
My Shopping Cart
FDA
FDA
About FDALive